BHVN Stock Summary and Trading Ideas (Biohaven Ltd. Common Shares | NYSE:BHVN)

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.

Biohaven Ltd. Common Shares trades on the NYSE stock market under the symbol BHVN.

As of November 13, 2024, BHVN stock price declined to $49.04 with 1,137,979 million shares trading.

BHVN has a beta of 1.79, meaning it tends to be more sensitive to market movements. BHVN has a correlation of 0.13 to the broad based SPY ETF.

BHVN has a market cap of $4.95 billion. This is considered a Mid Cap stock.

In the last 3 years, BHVN traded as high as $152.56 and as low as $7.10.

The top ETF exchange traded funds that BHVN belongs to (by Net Assets): VTI, IWM, VB, XBI, VBR.

BHVN has outperformed the market in the last year with a return of +71.5%, while the SPY ETF gained +37.1%. In the last 3 month period, BHVN beat the market returning +32.6%, while SPY returned +12.3%. However, in the most recent 2 weeks BHVN has underperformed the stock market by returning -3.7%, while SPY returned +2.7%.

BHVN support price is $48.96 and resistance is $51.76 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BHVN shares will trade within this expected range on the day.